SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and
commercialization of targeted therapies for women’s cancers, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00